Treatment of contaminated bone defects with clindamycin-reconstituted bone xenograft-composites

Journal of Biomedical Materials Research - Part B Applied Biomaterials

Volumn 82, Issue 2, 2007, Pages 418-427

  Bi, Long ^a   Hu, Yunyu ^a   Fan, Hongbin ^a   Meng, Guolin ^a   Liu, Jian ^a   Li, Dan ^a   Lv, Rong ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Bioactive material; Bone graft; Drug delivery release

Indexed keywords

ANTIBIOTICS; BIOACTIVITY; BIOCOMPATIBILITY; BONE; COMPOSITE MATERIALS; DRUG DELIVERY; PROTEINS;

BIOACTIVE MATERIAL; BONE GRAFT; DRUG RELEASE;

PATIENT TREATMENT;

BONE MORPHOGENETIC PROTEIN; CLINDAMYCIN;

ARTICLE; BIOCOMPATIBILITY; BONE DEFECT; BONE GRAFT; BONE INFECTION; CELL ULTRASTRUCTURE; CLINDAMYCIN RECONSTITUTED BONE XENOGRAFT COMPOSITE; COMPOSITE GRAFT; CONTAMINATION; DRUG RELEASE; NONHUMAN; OSTEOMYELITIS; RABBIT; RADIUS; SCANNING ELECTRON MICROSCOPY; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-BACTERIAL AGENTS; BONE DISEASES, INFECTIOUS; BONE MORPHOGENETIC PROTEINS; BONE REGENERATION; BONE SUBSTITUTES; CATTLE; CLINDAMYCIN; FRACTURES, BONE; MICE; RABBITS; STAPHYLOCOCCUS AUREUS;

EID: 34547127131     PISSN: 15524973     EISSN: 15524981     Source Type: Journal    
DOI: 10.1002/jbm.b.30747     Document Type: Article

References (59)

1. Korkusuz F, Korkusuz P, Eksioglu F, Gursel I, Hasirci V. In vivo response to biodegradable controlled antibiotic release systems. J Biomed Mater Res 2001;55:217-228.
2. Shinto Y, Uchida A, Korkusuz F, Araki N, Ono K. Calcium hydroxyapatite ceramic used as a delivery system for antibiotics. J Bone Joint Surg Br 1992;74:600-604.
3. Cornell CN, Tyndall D, Waller S, Lane JM, Brause BD. Treatment of experimental osteomyelitis with antibiotic-impregnated bone graft substitute. J Orthop Res 1993;11:619-626.
4. Gerhart TN, Roux RD, Horowitz G, Miller RL, Hanff P, Hayes WC. Antibiotic release from an experimental biodegradable bone cement. J Orthop Res 1988;6:585-592.
5. Garvin K, Feschuk C. Polylactide-polyglycolide antibiotic implants. Clin Orthop Relat Res 2005;437:105-110.
6. Kanellakopoulou K, Giamarellos-Bourboulis EJ. Carrier systems for the local delivery of antibiotics in bone infections. Drugs 2000;59:1223-1232.
7. Holtom PD, Patzakis MJ. Newer methods of antimicrobial delivery for bone and joint infections. Instr Course Lect 2003;52:745-749.
8. Wahlig H. Gentamicin-PMMA-beads: A drug delivery system in the treatment of chronic bone and soft tissue infections. J Antimicrob Chemother 1982;10:463-465.
9. Stabile DE, Jacobs AM. Development and application of antibiotic-loaded bone cement beads. J Am Podiatr Med Assoc 1990;80:354-359.
10. Perry A, Mahar A, Massie J, Arrieta N, Garfin S, Kim C. Biomechanical evaluation of kyphoplasty with calcium sulfate cement in a cadaveric osteoporotic vertebral compression fracture model. Spine J 2005;5:489-493.
11. Stevens CM, Tetsworth KD, Calhoun JH, Mader JT. An articulated antibiotic spacer used for infected total knee arthroplasty: A comparative in vitro elution study of Simplex and Palacos bone cements. J Orthop Res 2005;23:27-33.
12. Yamanura K, Iwata H, Yotsuyanagi T. Synthesis of antibiotic-loaded hydroxyapatite beads and in vitro drug release testing. J Biomed Mater Res 1992;26:1053-1064.
13. El-Ghannam A. Bone reconstruction: From bioceramics to tissue engineering. Expert Rev Med Devices 2005;2:87-101.
14. Jacob E, Cierny G, Zorn K, McNeill JF, Fallon MT. Delayed local treatment of rabbit tibial fractures with biodegradable cefazolin microspheres. Clin Orthop Relat Res 1997;336:278-285.
15. Garvin KL, Miyano JA, Robinson D, Giger D, Novak J, Radio S. Polylactide/polyglycolide antibiotic implants in the treatment of osteomyelitis: A canine model. J Bone Joint Surg Am 1994; 76:1500-1506.
16. Kim HW, Knowles JC, Kim HE. Hydroxyapatite/poly (ε-caprolactone) composite coatings on hydroxyapatite porous bone scaffold for drug delivery. Biomaterials 2004;25(7/8):1279-1287.
17. Gazdag AR, Lane JM, Glaser D, Forster RA. Alternatives to autogenous bone graft: Efficacy and indications. J Am Acad Orthop Surg 1995;3:1-8.
18. Giannoudis PV, Dinopoulos H, Tsiridis E. Bone substitutes: An update. Injury 2005;36(Suppl 3):S20-S27.
19. Liu Wei, Hu Yunyu, Lu Yupu, Wang Yuqing. Development and biological activity analysis of reconstituted bone xenograft. Natl Med J China 1991;71:378-380.
20. Li Dan Sang Hongxun, Hu Yunyu, Yan Zhi, Yang Liu, Ma Shengbin. The effect of technological improvements on yield rate and bioactivity of the product in bBMP extraction. Orthop J China 2001;8:576-578.
21. Li Yafei, Hu Yunyu, Li Xuebing, Yang Guang, Cong Rui, Li Huanlin. Influence of geometry of bone particles and intensely stirring of the extraction on the yield of bBMP and its osteoinductivity. Chin J Orthop 1996;16:118-120.
22. Guo Zheng, Hu Yunyu, Lin Yinghua. Ultrastructural observation of heterotopic bone formation induced by bovine bone morphogenetic protein. J Fourth Milit Med Univ 1996;17: 407-411.
23. Hu YY. Experimental studies on reconstituted bone xenograft and its clinical application. Zhonghua Wai Ke Za Zhi 1993; 31:709-713.
24. Urist MR. Bone: Formation by autoinduction. 1965. Clin Orthop Relat Res 2002;395:4-10.
25. Urist MR, Mikulski A, Lietze A. Solubilized and insolubilized bone morphogenetic protein. Proc Natl Acad Sci USA 1979; 76:1828-1832.
26. Urist MR, Chang JJ, Lietze A. Preparation and bioassay of bone morphogenetic protein and polypeptide fragments. Methods Enzymol 1987;146:294-312.
27. Ohta H, Wakitani S, Tensho K, Horiuchi H, Wakabayashi S, Saito N, Nakamura Y, Nozaki K, Imai Y, Takaoka K. The effects of heat on the biological activity of recombinant human bone morphogenetic protein-2. J Bone Miner Metab 2005;23: 420-425.
28. Miki T, Imai Y. Osteoinductive potential of freeze-dried, biodegradable, poly (glycolic acid-co-lactic acid) disks incorporated with bone morphogenetic protein in skull defects of rats. Int J Oral Maxillofac Surg 1996;25:402-406.
29. Shi Guixin, Wang Shenguo, Bei Jianzhong. Preparation of porous cell scaffolds of poly (L-lactic acid) and poly (L-lactic- co-glycolic acid) and the measurement of their porosity. J Funct Polym 2001;149:7-11.
30. Chaitram JM, Jevitt LA, Lary S, Tenover FC. The World Health Organization's External Quality Assurance System Proficiency Testing Program has improved the accuracy of antimicrobial susceptibility testing and reporting among participating laboratories using NCCLS methods. J Clin Microbiol 2003;41:2372-2377.
31. Yoshimoto H, Shin YM, Terai H, Vacanti JP. A biodegradable nanofiber scaffold by electrospinning and its potential for bone tissue engineering. Biomaterials 2003;24:2077-2082.
32. Herold RW, Pashley DH, Cuenin MF, Niagro F, Hokett SD, Peacock ME, Mailhot J, Borke J. The effects of varying degrees of allograft decalcification on cultured porcine osteoclast cells. J Periodontol 2002;73:213-219.
33. Beardmore AA, Brooks DE, Wenke JC, Thomas DB. Effectiveness of local antibiotic delivery with an osteoinductive and osteoconductive bone-graft substitute. J Bone Joint Surg Am 2005;87:107-112.
34. Redondo LM, Garcia Cantera JM, Verrier Hernandez A, Vaquero PC. Effect of particulate porous hydroxyapatite on osteoinduction of demineralized bone autografts in experimental reconstruction of the rat mandible. Int J Oral Maxillofac Surg 1995;24:445-448.
35. Dai Honglian, L I Shipu, Yan Yuhua, Li Xiaoxi, Jia Li. The osteogenesis process of tricalcium phosphate ceramics in vivo. Trans Nonferrous Met Soc China 2003;13:65-68.
36. Urist MR. Bone: Formation by autoinduction. Science 1965; 150:893-899.
37. Matthews SJ. Biological activity of bone morphogenetic proteins (BMPs). Injury 2005;36 (Suppl 3):S34-S37.
38. De Biase P, Capanna R. Clinical applications of BMPs. Injury 2005;36(Suppl 3):S43-S46.
39. Dutta Roy T, Simon JL, Ricci JL, Rekow ED, Thompson VP, Parsons JR. Performance of hydroxyapatite bone repair scaffolds created via three-dimensional fabrication techniques. J Biomed Mater Res A 2003;67:1228-1237.
40. Wang ZG, Liu J, Hu YY, Meng GL, Jin GL, Yan Z, Wang HQ, Dai XW. Treatment of tibial defect and bone nonunion with limb shortening with external fixator and reconstituted bone xenograft. Chin J Traumatol 2003;6:91-98.
41. Meseguer-Olmo L, Ros-Nicolas M, Vicente-Ortega V, Alcaraz M, Clavel M, Arcos D, Vallet-Regi M, Meseguer-Ortiz C. A bioactive sol-gel glass implant for in vivo gentamicin release. Experimental model in rabbit. J Orthop Res 2006;24:454-460.
42. Salvi GE, Mombelli A, Mayfield L, Andrea ML, Rutar AS, Jean GS, Lang NP. Local antimicrobial therapy after initial periodontal treatment. J Clin Periodontol 2002;29:540-550.
43. Hu Y, Zhang C, Zhang S, Xiong Z, Xu J. Development of a porous poly(L-lactic acid)/hydroxyapatite/collagen scaffold as a BMP delivery system and its use in healing canine segmental bone defect. J Biomed Mater Res A 2003;67:591-598.
44. Sun L, Hu YY, Xiong Z, Wang WM, Pan Y. Repair of the radial defect of rabbit by polyester/tricalcium phosphate scaffolds prepared by rapid prototyping technology. Zhonghua Wai Ke Za Zhi 2005;43:535-539.
45. Liu G, Hu YY, Zhao JN, Wu SJ, Xiong Z, Lu Rong. Effect of type I collagen on the adhesion, proliferation, and osteoblastic gene expression of bone marrow-derived mesenchymal stem cells. Chin J Traumatol 2004;7:358-362.
46. Hu YY, Zhang C, Lu R. Repair of radius defect with bone-morphogenetic- protein loaded hydroxyapatite/collagen-poly (L-lactic acid) composite. Chin J Traumatol 2003;6:67-74.
47. Mader JT, Adams K, Morrison L. Comparative evaluation of Cefazolin and Clindamycin in the treatment of experimental Staphylococcus aureus osteomyelitis in rabbits. Antimicrob Agents Chemother 1989;33:1760-1764.
48. Flaherty JF, Rodondi LC, Guglielmo BJ, Fleishaker JC, Townsend RJ, Gambertoglio JG. Comparative pharmacokinetics and serum inhibitory activity of clindamycin in different dosing regimens. Antimicrob Agents Chemother 1988;32: 1825-1829.
49. Foppa CU, Bini T, Gregis G, Lazzarin A, Esposito R, Moroni M. A retrospective study of primary and maintenance therapy of toxoplasmic encephalitis with oral clindamycin and pyrimethamine. Eur J Clin Microbiol Infect Dis 1991;10:187-189.
50. Brook I. Pseudomembranous colitis in children. J Gastroenterol Hepatol 2005;20:182-186.
51. Xu Xiaogang, Li Guanghui. Guidelines of antimicrobial agent prophylaxis in surgery. Chin J Infect Chemother 2005;5:180-183.
52. Schentag JJ, Gilliland KK, Paladino JA. What have we learned from pharmacokinetic and pharmacodynamic theories? Clin Infect Dis 2001;32(Suppl 1):S39-S46.
53. Nakano T, Hiramatsu K, Kishi K, Hirata N, Kadota J, Nasu M. Clindamycin modulates inflammatory-cytokine induction in lipopolysaccharide-stimulated mouse peritoneal macrophages. Antimicrob Agents Chemother 2003;47:363-367.
54. Heckman JD, Ehler W, Brooks BP, Aufdemorte TB, Lohmann CH, Morgan T, Boyan BD. Bone morphogenetic protein but not transforming growth factor-β enhances bone formation in canine diaphyseal nonunions implanted with a biodegradable composite polymer. J Bone Joint Surg Am 1999;81:1717-1729.
55. Li XD, Hu YY. The treatment of osteomyelitis with gentamicin- reconstituted bone xenograft-composite. J Bone Joint Surg Br 2001;83:1063-1068.
56. Zalavras CG, Patzakis MJ, Holtom P. Local antibiotic therapy in the treatment of open fractures and osteomyelitis. Clin Orthop Relat Res 2004;427:86-93.
57. Gil-Albarova J, Salinas AJ, Bueno-Lozano AL, Roman J, Aldini-Nicolo N, Garcia-Barea A, Giavaresi G, Fini M, Giardino R. The in vivo behaviour of a sol-gel glass and a glass-ceramic during critical diaphyseal bone defects healing. Biomaterials 2005;26:4374-4382.
58. Dodde R II, Yavuzer R, Bier UC, Alkadri A, Jackson IT. Spontaneous bone healing in the rabbit. J Craniofac Surg 2000; 11:346-349.
59. Garvin KL, Hanssen AD. Infection after total arthroplasty. Past, present, and future. J Bone Joint Surg Am 1995;77:1576-1588.